Nivolumab as first-line treatment in non-small cell lung cancer patients-key factors: tumor mutation burden and PD-L1 ≥50.
Τίτλος | Nivolumab as first-line treatment in non-small cell lung cancer patients-key factors: tumor mutation burden and PD-L1 ≥50. |
Publication Type | Journal Article |
Year of Publication | 2018 |
Authors | Zarogoulidis, P., Papadopoulos V., Maragouli E., Papatsibas G., Sardeli C., Man Y-G., Bai C., & Huang H. |
Journal | Transl Lung Cancer Res |
Volume | 7 |
Issue | Suppl 1 |
Pagination | S28-S30 |
Date Published | 2018 Feb |
ISSN | 2218-6751 |
DOI | 10.21037/tlcr.2018.01.04 |
Alternate Journal | Transl Lung Cancer Res |
PubMed ID | 29531900 |
PubMed Central ID | PMC5835639 |